← Back to Blog
Atmospheric illustration of a woman sitting on the edge of her bed at 3 AM, fingertips at her temple, a half-empty glass of water and open blister pack on the nightstand — the failed-triptan moment the article opens with
Tips

When Triptans Stop Working: Tachyphylaxis, Switching, and What Comes Next

Sumatriptan used to work in 20 minutes. Now it barely touches the pain. Tachyphylaxis is real, it's underdiscussed, and there's a clear pathway out — rizatriptan, eletriptan, gepants, lasmiditan. A decision tree your neurologist may not have walked you through.

📅 May 2026 ⏱ 7 min read ✍️ Rustam Iuldashov

By Rustam Iuldashov

30 years lived experience with chronic migraine | Sources: 30 peer-reviewed references including Cephalalgia, JAMA, Annals of Neurology, Journal of Headache and Pain, Nature Communications, BMC Neurology, Headache, Drugs, Cochrane Database, Nature Reviews Neurology | Last updated: May 2026

Important Notice: This article is for informational and educational purposes only and does not constitute medical advice. The author is not a licensed physician. Always consult your neurologist before starting, stopping, switching, or combining migraine medications. For medical emergencies, call 911 immediately.

Key Takeaways

  • Triptan tachyphylaxis is real, but four reversible problems mimic it: late dosing, MOH, disease progression, and partial-response-all-along.[1,2,3]
  • Treating before cutaneous allodynia raises pain-free response from 15% to 93% in the same patient.[5]
  • Failure of one triptan does not predict failure of others. Eletriptan and rizatriptan are the strongest second choices.[11,12]
  • Sumatriptan + naproxen combination outperforms either drug alone.[16,17]
  • Gepants (ubrogepant, rimegepant) and lasmiditan are evidence-based options for triptan non-responders.[19,20,23]
  • Using triptans 10+ days a month likely causes MOH. Switching drugs without addressing this will not help.[6,27]
  • If your acute treatment keeps failing, the question may be prevention — not another abortive.[30]

The first time it worked, it felt like sorcery. Fifty milligrams of sumatriptan. Twenty minutes. The throb behind your eye dissolved, and you got your evening back.

Years pass. Then one Tuesday the pill lands like a sugar tablet. You take another. Still nothing. By hour three you are curled in the dark counting heartbeats and wondering if you have somehow broken the drug.

You haven't broken the drug. But something real is happening, and it has a name.

What's actually going on

Doctors call it tachyphylaxis — the loss of response to a medication you used to tolerate well.[1] It is more common than most patients realize. A German registry of 2,284 migraine patients in specialist headache care found that 42.5% had failed at least one triptan, 13.1% had failed two or more, and 3.9% had failed three or more.[2] The European Headache Federation now formally defines triptan resistance as failure of two or more triptans, and triptan refractory as failure of three or more, including the subcutaneous form.[3]

But "tachyphylaxis" is also a lazy label. Before you accept that the entire drug class is done with you, rule out four other explanations. Three of them are reversible.

Explanation 1: You're taking it too late. Triptans bind 5-HT1B/1D receptors on the trigeminovascular system, blocking pain-signaling peptides before central sensitization sets in.[4] Once the migraine generates cutaneous allodynia — when brushing your hair or wearing glasses starts to hurt — that window has closed. In a landmark study, patients given a triptan after allodynia developed became pain-free in only 15% of attacks. Treated before allodynia, the same patients became pain-free in 93%.[5]

Explanation 2: You're taking it too often. Triptans cause medication overuse headache when used on 10 or more days per month for three months.[6] Paradoxically, the drug that abolished your attacks now causes them — and dulls itself in the process.[7] This is the most under-recognized cause of triptan "failure" in primary care.

Explanation 3: Your migraine has changed. Migraine can transform from episodic to chronic over years, and what worked at four attacks per month may not work at twelve.

Explanation 4: You were never the full responder you thought. The EHF defines a triptan-responder as someone for whom the drug effectively treats 3 of 4 attacks.[3] A partial responder from day one is not the same as someone who developed tolerance — and the next step differs.

⚠️ When to seek emergency care, not another pill

Most of the time, a failed triptan means a worse migraine — not a medical emergency. But certain warning signs require immediate evaluation, not a switch in medication. Call emergency services or go to the nearest emergency department if you experience:

  • The worst headache of your life with sudden, thunderclap onset (peaks in under 60 seconds)
  • Headache with fever, stiff neck, confusion, or rash
  • Headache with new neurological symptoms — weakness on one side, slurred speech, vision loss, loss of balance, or seizure
  • Headache after a head injury, especially with vomiting or drowsiness
  • Chest pain, jaw pain, or shortness of breath after taking a triptan (possible vasoconstrictive event)
  • A migraine that has lasted more than 72 hours without relief (status migrainosus)

Triptans are contraindicated in people with a history of ischemic heart disease, stroke, uncontrolled hypertension, or peripheral vascular disease. If you have any of these conditions and have been prescribed a triptan, talk to your neurologist about switching to a gepant or lasmiditan — both work without vasoconstriction.[21]

Atmospheric illustration of Anna at her kitchen table the morning after a failed triptan, building a hand-drawn decision tree in her notebook with three medication boxes laid out beside her laptop — the moment of taking ownership of the treatment plan
The morning after a failed pill. The decision tree starts not in a clinic, but at your own table — with documentation, questions, and a list. Sources: EHF consensus, Sacco et al., 2022; AHS position statement, Charles et al., 2024.

Step 1: Change how you take it, before you change what you take

Three free experiments come before switching drugs.

Take it earlier. Many patients, taught to fear overuse, wait until the pain is "real." This is exactly backwards. Treat at first warning, during the mild headache phase, before allodynia.[5,8]

Change the route. Oral sumatriptan 100 mg has a number-needed-to-treat (NNT) of 3.0 at 2 hours. Subcutaneous sumatriptan 6 mg has an NNT of 2.0 at 1 hour — twice as fast, more effective.[9] Nasal sprays sit in between.[10] If your stomach shuts down during attacks — the gastric stasis of migraine — oral tablets may not be absorbing at all.

Treat the morning attack, not the breakthrough. If your migraine reliably wakes you at 4 a.m., dose within minutes of waking.

Step 2: Switch within the triptan class

Here is the fact that surprises most patients: failure of one triptan does not predict failure of others. Four randomized trials of alternative triptans in sumatriptan non-responders showed meaningful response in the majority of patients.[11]

A 2014 multiple-treatment-comparison meta-analysis of 74 randomized trials produced a clear hierarchy:[12]

  • Eletriptan 80 mg topped both the 2-hour pain-free and 24-hour sustained response rankings, beating sumatriptan, almotriptan, naratriptan, and frovatriptan.
  • Rizatriptan 10 mg ranked second at 2 hours but did not hold its 24-hour edge.
  • Zolmitriptan and high-dose sumatriptan clustered in the next tier.
  • Naratriptan 2.5 mg is the slowest-acting but, with a 5–8-hour half-life, has the lowest recurrence rate — 17–27% lower than sumatriptan.[13]
  • Frovatriptan, with a 26–30-hour half-life, is the gentlest and longest-lasting — useful for menstrual migraine and long-tail attacks.[14]

If your sumatriptan does not work, the next step is eletriptan or rizatriptan, not more sumatriptan. An open-label trial of patients dissatisfied with rizatriptan found meaningful relief on switching to eletriptan.[15] The triptans are not interchangeable. Pharmacokinetics matter.

Step 3: Add naproxen, or switch to the combination pill

A fixed-dose sumatriptan 85 mg + naproxen sodium 500 mg combination outperformed either drug alone in two large trials, with 2-hour pain relief of 65% vs 28% in the first study and 57% vs 29% in the second.[16] The 24-hour sustained pain-free response is also significantly better than monotherapy.[17]

The mechanism makes sense: triptans block the trigeminovascular signal early; naproxen damps the inflammatory cascade behind it. If you cannot get the combination pill, taking your usual triptan with 500 mg of naproxen sodium achieves the same effect, supported by a pragmatic crossover trial.[18]

The triptans are not interchangeable. Failure of one does not predict failure of the next. Pharmacokinetics matter — and the next pill is usually different, not stronger.

Step 4: Switch class — gepants

If two adequately-dosed, well-timed triptans have failed you, you are now triptan-resistant by EHF criteria.[3] You qualify for the next class: gepants — small-molecule CGRP receptor antagonists.

The two oral acute-treatment gepants are ubrogepant (50 mg or 100 mg) and rimegepant (75 mg orally disintegrating). A post-hoc analysis of the ACHIEVE I and II trials showed ubrogepant produced favorable 2-hour functional outcomes in self-reported triptan-insufficient responders, with no new safety signals.[19] A 2024 network meta-analysis of randomized trials in this exact population found all three novel agents — lasmiditan, rimegepant, and ubrogepant — effective, with high-dose lasmiditan ranking highest for pain control.[20]

Two things make gepants particularly useful when triptans fail:

  • No vasoconstriction. They do not squeeze blood vessels, so they are appropriate for patients with coronary disease, prior stroke, or uncontrolled hypertension — patients for whom triptans are contraindicated.[21]
  • No MOH risk. Gepants do not appear to cause medication overuse headache. Some are even used preventively (rimegepant every other day, atogepant daily).[22]

Step 5: Lasmiditan — the ditans

Lasmiditan (50, 100, or 200 mg) is the first of a new class called ditans: selective 5-HT1F agonists with no meaningful 5-HT1B activity, and therefore no vasoconstriction.[23] In the CENTURION trial and post-hoc analyses of SAMURAI and SPARTAN, lasmiditan worked equally well in patients with prior good or poor response to triptans.[24,25]

The caveat is large enough to plan around. Lasmiditan causes dose-dependent dizziness, sedation, and measurable driving impairment. FDA labeling requires patients not to drive or operate machinery for at least eight hours after a dose.[26] This makes lasmiditan best suited to evening attacks, weekend attacks, and patients who can stop work for the day.

Step 6: If you're using triptans more than twice a week, treat the MOH first

Switching drugs does not fix medication overuse headache. If you are taking a triptan on more than 10 days per month, the path forward is stopping the overused medication and starting a preventive.[27,28] Things get worse before they get better, usually for two to ten days. But headache frequency drops meaningfully in 37–46% of patients within three months.[29]

Where prevention comes in

The American Headache Society's 2024 position statement now lists CGRP-targeting preventives — monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) and gepants used preventively (atogepant, rimegepant) — as a first-line option for migraine prevention, no longer requiring failure of older preventives first.[30] If your acute medication keeps failing because your migraine load is too high, prevention is the lever, not another abortive.

Atmospheric illustration of Anna in conversation with her neurologist across a wooden desk, her notebook open between them showing a hand-drawn branching decision tree, morning light pouring through the window — the empowered patient appointment
The conversation that should be happening. Notebook open, questions ready, decision tree on the page — and a neurologist who listens because the patient is presenting evidence. Sources: AHS 2024 position statement; EHF triptan failure consensus, 2022.

🗺️ The Decision Tree Your Neurologist May Not Have Walked You Through

  1. Taking it within 30 minutes of pain onset? If no — fix that first.
  2. Oral form failing because of nausea or slow absorption? Try nasal or subcutaneous.
  3. Only sumatriptan has failed? Ask for eletriptan or rizatriptan.
  4. Response weakening mid-attack? Add naproxen, or switch to a longer-half-life triptan (naratriptan, frovatriptan).
  5. Two triptans failed? You are triptan-resistant — request ubrogepant or rimegepant.
  6. Cardiovascular contraindication to triptans? Skip straight to a gepant or lasmiditan.
  7. Using acute meds 10+ days a month? Address MOH first, then start a preventive.
  8. Frequent attacks? Consider CGRP preventive therapy.

The drug you started on twenty years ago is not the only door. There are eight more.

Key Takeaways

  • Triptan tachyphylaxis is real, but four reversible problems mimic it: late dosing, MOH, disease progression, and partial-response-all-along.
  • Treating before cutaneous allodynia raises pain-free response from 15% to 93% in the same patient.
  • Failure of one triptan does not predict failure of others. Eletriptan and rizatriptan are the strongest second choices.
  • Sumatriptan + naproxen combination outperforms either drug alone.
  • Gepants (ubrogepant, rimegepant) and lasmiditan are evidence-based options for triptan non-responders.
  • Using triptans 10+ days a month likely causes MOH. Switching drugs without addressing this will not help.
  • If your acute treatment keeps failing, the question may be prevention — not another abortive.

Deepen Your Understanding

The CGRP Revolution

The science behind the new class of migraine medications — how CGRP inhibitors work differently from everything before them.

Gepants: The New Acute Medications

Nurtec, Ubrelvy, Qulipta — how the oral CGRP blockers work, who they're for, and how they fit when triptans fail.

Medication Overuse Headache

The 10-days-a-month threshold that turns relief into rebound. How to recognize it, how to break the cycle.

Cutaneous Allodynia

When brushing your hair starts to hurt: the central sensitization that closes the triptan treatment window — and what to do about it.

⚕️ Full Medical Disclaimer

This article is written by Rustam Iuldashov, a patient with 30 years of personal experience living with migraine. It is intended for educational and informational purposes only and does not constitute medical advice. The author is not a licensed physician.

Triptans, gepants, ditans, and CGRP monoclonal antibodies are prescription medications with specific contraindications, drug interactions, and dosing rules. Do not start, stop, switch, or combine any of these medications without consulting your neurologist or primary care physician. In particular, never combine two triptans within 24 hours, never combine a triptan with an MAO inhibitor, and discuss any history of cardiovascular disease, pregnancy, or use of SSRIs/SNRIs (serotonin syndrome risk) before starting any new acute migraine medication.

The "decision tree" in this article is a structured conversation starter for your medical appointment — not a prescribing algorithm. Every patient's history, comorbidities, and treatment goals are different, and only your physician can build a plan that is right for you. If you are experiencing a severe or unusual headache, the symptoms listed in the emergency box above, or a sudden change in your migraine pattern, seek medical care without delay.

References & Further Reading

  1. GHLF Editorial Board. "Signs Your Migraine Treatment Stopped Working — and What to Do If It Does." Global Healthy Living Foundation (2023). ghlf.org. Clinical commentary with expert input.
  2. Beier D, Schulte LH, Gaul C, et al. "Triptan non-response in specialized headache care: cross-sectional data from the DMKG Headache Registry." Journal of Headache and Pain 24:130 (2023). doi:10.1186/s10194-023-01664-4. Cross-sectional registry. n=2,284.
  3. Sacco S, Lampl C, Amin FM, et al. "European Headache Federation (EHF) consensus on the definition of effective treatment of a migraine attack and of triptan failure." Journal of Headache and Pain 23:133 (2022). doi:10.1186/s10194-022-01502-z. Delphi consensus.
  4. Hou Y, Yang S, Zhu X, et al. "Lasmiditan mechanism of action — review of a selective 5-HT1F agonist." Journal of Headache and Pain 21:71 (2020). doi:10.1186/s10194-020-01132-3. Mechanistic review.
  5. Burstein R, Collins B, Jakubowski M. "Defeating migraine pain with triptans: a race against the development of cutaneous allodynia." Annals of Neurology 55(1):19–26 (2004). doi:10.1002/ana.10786. Prospective clinical study. n=31, 61 attacks.
  6. Headache Classification Committee of the International Headache Society. "ICHD-3, 8.2.2 Triptan-overuse headache." Cephalalgia 38(1):1–211 (2018). doi:10.1177/0333102417738202. International diagnostic criteria.
  7. Bonnet C, Hao J, Osorio N, et al. "Maladaptive activation of Nav1.9 channels by nitric oxide causes triptan-induced medication overuse headache." Nature Communications 10:4253 (2019). doi:10.1038/s41467-019-12197-3. Preclinical mechanistic study.
  8. Hu Y, Guan X, Fan L, Jin L. "Triptans in prevention of menstrual migraine: a systematic review with meta-analysis." Journal of Headache and Pain 14:7 (2013). doi:10.1186/1129-2377-14-7. Systematic review and meta-analysis.
  9. Tfelt-Hansen P. "Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat." Cephalalgia 18(8):532–538 (1998). doi:10.1046/j.1468-2982.1998.1808532.x. Systematic review of 30 RCTs. n>5,400.
  10. Derry CJ, Derry S, Moore RA. "Sumatriptan (all routes of administration) for acute migraine attacks in adults — overview of Cochrane reviews." Cochrane Database of Systematic Reviews CD009108 (2014). doi:10.1002/14651858.CD009108.pub2. Cochrane systematic review. n>50,000.
  11. Dahlöf CGH. "Infrequent or non-response to oral sumatriptan does not predict response to other triptans — review of four trials." Cephalalgia 26(2):98–106 (2006). doi:10.1111/j.1468-2982.2005.01010.x. Systematic review of 4 switching trials.
  12. Thorlund K, Mills EJ, Wu P, et al. "Comparative efficacy of triptans for the abortive treatment of migraine: a multiple treatment comparison meta-analysis." Cephalalgia 34(4):258–267 (2014). doi:10.1177/0333102413508661. Network meta-analysis of 74 RCTs.
  13. Tfelt-Hansen P. "Naratriptan is as effective as sumatriptan for the treatment of migraine attacks when used properly. A mini-review." Cephalalgia 41(14):1499–1505 (2021). doi:10.1177/03331024211028959. Mini-review of RCTs.
  14. Tfelt-Hansen P, De Vries P, Saxena PR. "Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy." Drugs 60(6):1259–1287 (2000). doi:10.2165/00003495-200060060-00003. Comparative pharmacology review.
  15. Stark S, Spierings ELH, McNeal S, et al. "Eletriptan in migraine patients reporting unsatisfactory response to rizatriptan." Headache 46(7):1142–1150 (2006). doi:10.1111/j.1526-4610.2006.00540.x. Open-label switching trial. n=223.
  16. Brandes JL, Kudrow D, Stark SR, et al. "Sumatriptan-naproxen for acute treatment of migraine: a randomized trial." JAMA 297(13):1443–1454 (2007). doi:10.1001/jama.297.13.1443. Two RCTs. n=2,956.
  17. Law S, Derry S, Moore RA. "Sumatriptan plus naproxen for the treatment of acute migraine attacks in adults." Cochrane Database of Systematic Reviews CD008541 (2016). doi:10.1002/14651858.CD008541.pub3. Cochrane systematic review.
  18. Smith T, Blumenthal H, Diamond M, et al. "Sumatriptan/naproxen sodium combination versus its components administered concomitantly for the acute treatment of migraine: a pragmatic, crossover, open-label outcomes study." Therapeutic Advances in Neurological Disorders 6(4):207–217 (2013). doi:10.1177/1756285613481084. Pragmatic crossover study.
  19. Lipton RB, Blumenfeld A, Jensen CM, et al. "Functionality, satisfaction, and global impression of change with ubrogepant for the acute treatment of migraine in triptan insufficient responders: a post hoc analysis of the ACHIEVE I and ACHIEVE II randomized trials." Journal of Headache and Pain 23:50 (2022). doi:10.1186/s10194-022-01418-8. Post-hoc analysis of two phase 3 RCTs.
  20. Laohapiboolrattana W, Jansem P, Anukoolwittaya P, et al. "Efficacy of lasmiditan, rimegepant and ubrogepant for acute treatment of migraine in triptan insufficient responders: systematic review and network meta-analysis." Journal of Headache and Pain 25:194 (2024). doi:10.1186/s10194-024-01904-1. Systematic review and network meta-analysis.
  21. Tepper SJ, Ailani J, Ford JH, et al. "Cardiovascular risk and triptan usage among patients with migraine." Headache 65(7):1135–1145 (2025). doi:10.1111/head.14979. Retrospective cohort study. n=26,054.
  22. Negro A, Martelletti P. "Gepants for the treatment of migraine." Expert Opinion on Investigational Drugs 28(6):555–567 (2019). doi:10.1080/13543784.2019.1618830. Pharmacology and clinical review.
  23. Reuter U, Krege JH, Lombard L, et al. "Lasmiditan efficacy in the acute treatment of migraine was independent of prior response to triptans: Findings from the CENTURION study." Cephalalgia 42(1):20–30 (2022). doi:10.1177/03331024211048507. Randomized controlled trial. n=1,471.
  24. Knievel K, Buchanan AS, Lombard L, et al. "Lasmiditan for the acute treatment of migraine: Subgroup analyses by prior response to triptans." Cephalalgia 40(1):19–27 (2020). doi:10.1177/0333102419889350. Post-hoc subgroup analysis of two phase 3 RCTs.
  25. Loo LS, Plato BM, Turner IM, et al. "Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine: findings from the phase 3 trials (SAMURAI and SPARTAN)." BMC Neurology 19:191 (2019). doi:10.1186/s12883-019-1420-5. Two phase 3 RCTs. n=3,981.
  26. Pearlman E, Wilbraham D, Dennehy EB, et al. "Effects of lasmiditan on simulated driving performance: Results of two randomized, blinded, crossover studies with placebo and active controls." Human Psychopharmacology 35(5):e2732 (2020). doi:10.1002/hup.2732. Two crossover RCTs.
  27. Diener HC, Holle D, Solbach K, Gaul C. "Medication-overuse headache: risk factors, pathophysiology and management." Nature Reviews Neurology 12(10):575–583 (2016). doi:10.1038/nrneurol.2016.124. Narrative review.
  28. Vandenbussche N, Laterza D, Lisicki M, et al. "Medication-overuse headache: a widely recognized entity amidst ongoing debate." Journal of Headache and Pain 19:50 (2018). doi:10.1186/s10194-018-0875-x. Review.
  29. Sarchielli P, Messina P, Cupini LM, et al. "Sodium valproate in migraine without aura and medication overuse headache: a randomized controlled trial." European Neuropsychopharmacology 24(8):1289–1297 (2014). doi:10.1016/j.euroneuro.2014.05.007. RCT. n=130.
  30. Charles AC, Digre KB, Goadsby PJ, et al. "Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update." Headache 64(4):333–341 (2024). doi:10.1111/head.14692. AHS consensus position statement.
Rustam Iuldashov

Rustam Iuldashov

Creator & Developer — 30 years living with migraine. Solo developer from Ukraine who built Migraine Companion during wartime. His approach combines first-hand patient experience with peer-reviewed medical research and narrative therapy principles (Michael White & David Epston). He is not a medical professional.

Transparency & Conflict of Interest Disclosure: Rustam is the developer of the Migraine Companion app mentioned in this article. He has no financial relationships with any pharmaceutical manufacturer mentioned, including makers of sumatriptan, eletriptan, rizatriptan, naratriptan, frovatriptan, zolmitriptan, almotriptan, ubrogepant (AbbVie/Allergan), rimegepant (Pfizer/Biohaven), zavegepant (Pfizer), lasmiditan (Eli Lilly/Reyvow), erenumab (Amgen/Novartis), fremanezumab (Teva), galcanezumab (Eli Lilly), eptinezumab (Lundbeck), or atogepant (AbbVie). No sponsored content. No affiliate links.

📧 Contact: mi-companion.com/contact · 🌐 Website: mi-companion.com

How We Create Content

  • Peer-reviewed sources only. Cephalalgia, JAMA, Annals of Neurology, Journal of Headache and Pain, Nature Communications, BMC Neurology, Headache, Drugs, Cochrane Database, Nature Reviews Neurology — plus the EHF consensus statement and AHS 2024 position statement.
  • Source transparency. Every clinical claim carries a numbered citation. Study design and sample size noted. DOI links provided.
  • Experience + Science. 30 years personal migraine experience combined with peer-reviewed evidence.
  • Regular updates. Articles are reviewed when significant new evidence or guideline changes appear.
  • No conflicts of interest. No funding from any pharmaceutical manufacturer or device maker.

Build the Evidence Before You Need It

Migraine Companion helps you log every attack with timing, severity, symptoms, medications tried, and what worked — the exact documentation that turns a vague conversation about "the pill stopped working" into a clear, evidence-backed case for switching treatment.

Last reviewed: May 2026

Next scheduled review: November 2026